New York City, New York

HomeNew YorkNew York City

Email Laurence Banville Laurence Banville on Twitter Laurence Banville on Facebook Laurence Banville on Avvo
Laurence Banville
Laurence Banville
Attorney • (917) 633-4808

Second Bellwether Case For Xarelto Lawsuit Filings Postponed Until April


TheProductLawyers.com reports on a recent postponement of bellwether trials involving Xarelto lawsuits. According to Consumer Advocacy News, U.S. District Judge Eldon E. Fallon, who is presiding over the Xarelto litigation has delayed the start of the first two bellwether trials.The first trial was originally scheduled for February 6, 2017, but will not take place until a month later on March 13, 2017. The second trial, which was originally scheduled for March 13, 2017, will now begin on April 24, 2017, according to the source.

Mass Tort Program

In addition to the more than 3,000 consolidated cases contained in the MDL, a mass tort program has been created in Philadelphia, Pennsylvania which currently houses over 600 cases. Those involved with the litigation anticipate bellwether trials for the mass tort to begin in August of 2017, but no dates have yet to be announced.

About The Drug

Xarelto, which was approved by the FDA in 2011, is a blood-thinning drug used for people with atrial fibrillation who are at an increased risk of forming a blood clot in the heart, which can travel to the brain or other parts of the body. The drug has been the subject of several warnings by the FDA since, including 2 black box warnings.

What Are The Allegations?

Side effects are the driving force behind why many patients have opted to file lawsuits against manufacturers AG Bayer and Johnson & Johnson. Plaintiffs have not only claimed that these side effects are life threatening but have also alleged that these companies were negligent in the marketing and sale of the products because of the lack of an antidote. Several of the lawsuits have been filed by family members who allege that a loved one died due to their use of the anticoagulant. The drug currently has no FDA-approved reversal agent to combat the risk of uncontrolled bleeding. These cases have been combined into an MDL in the Eastern District of Louisiana.

Leave a Comment

Have an opinion? Please leave a comment using the box below.

For information on acceptable commenting practices, please visit Lifehacker's guide to weblog comments. Comments containing spam or profanity will be filtered or deleted.